There have been multiple warnings and recalls of blood pressure medicines and Zantac. This issue summarizes their current status and safety risks.
Statement on New Testing Results, Including Low Levels of Impurities in Ranitidine Drugs
Over the past several weeks, the FDA has been investigating the detection of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications, commonly known by the brand name Zantac. Although many of the levels of NDMA observed through FDA testing are much lower than the levels some third-party scientists first claimed, some levels still exceed what the FDA considers acceptable for these medicines.
Valsartan, Losartan and Other BP Med Recalls 2018-19
Dozens of medications used to treat high blood pressure have been recalled over the past several months as federal investigators discover potentially cancer-causing impurities in them.
These common prescription drugs include valsartan, losartan, and irbesartan in different combinations and from different manufacturers.
“After 75 recalls it is clear more aggressive action is needed,” PIRG consumer watchdog Adam Garber said in a release.
U.S. Agency Sees Low Risk in Contaminated Blood Pressure Drugs
U.S. health officials in August tried to reassure patients that they face very low risks from ongoing contamination problems with widely prescribed blood pressure drugs.
Drugmakers have issued more than 50 recalls since last July linked to low levels of a probable cancer-causing chemical found in generic drugs taken by millions of Americans. The contamination underscores the Food and Drug Administration’s struggle to police an industry that increasingly relies on overseas manufacturing plants in China and India.